



LEW
\$

PATENT
Customer No. 22,852
Attorney Docket No. 09367.0084

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Gustave BERGNES *et al.*) Group Art Unit: 1624
)
Application No.: 10/626,012) Examiner: Tamthom Ngo TRUONG
)
Filed: July 23, 2003)
) Confirmation No.: 9951
For: COMPOUNDS, COMPOSITIONS,)
AND METHODS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In a restriction requirement, mailed November 18, 2005, the Examiner required
restriction under 35 U.S.C. § 121 between:

Group 1: Claims 1, 11, 15, 16, and 23 (in part), drawn to compounds of
formula I with V as a bond, **or** compounds of formula II wherein W, Z, Y and Z all represent C,
and V is a bond; pharmaceutical composition and kit thereof, classified in class 544, various
subclasses depending on substituents;

Group 2: Claims 1-6, 8, 9, 11, 15, 16, and 23 (in part), drawn to compounds
of formula I with V as NR'', **or** compounds of formula II wherein W, Z, Y and Z all represent
C, and V is NR''; pharmaceutical composition and kit thereof, classified in class 544, various
subclasses depending on substituents;

Group 3: Claims 1-4, 7-11, 15, 16, and 23 (in part), drawn to compounds of formula I with V as CR'R'', or compounds of formula II wherein W, Z, Y and Z all represent C, and V is CR'R''; pharmaceutical composition and kit thereof, classified in class 544, various subclasses depending on substituents;

Group 4: Claims 12-14 (in part), drawn to a method of treating a cellular proliferative disease using compounds of formula I with V as a bond; pharmaceutical composition and kit thereof, classified in class 514, various subclasses depending on substituents.

Group 5: Claims 12-14 (in part), drawn to compounds of formula I with V as NR'', classified in class 514, various subclasses depending on substituents.

Group 6: Claims 12-14 (in part), drawn to compounds of formula I with V as CR'R'', classified in class 514, various subclasses depending on substituents;

Group 7: Claims 16-19 and 23 (in part), drawn to the remaining compounds of formula II that are not mentioned in Groups 1-3 (i.e., **not** a substituted *quinazoline*), and pharmaceutical composition thereof, classified in class 544, various subclasses depending on substituents; and

Group 8: Claims 20-22 (in part), drawn to the method of treating a cellular proliferative disease using compounds of formula II that are not mentioned in Groups 1-3 (i.e., **not** a substituted *quinazoline*), and pharmaceutical composition thereof, classified in class 544, various subclasses depending on substituents.

Applicants elect without traverse Group 2, Claims 1-6, 8, 9, 11, 15, 16, and 23 (in part), drawn to compounds of formula I with V as NR'', or compounds of formula II wherein W, Z, Y

wherein W, Z, Y and Z all represent C, and V is NR'''; pharmaceutical composition and kit thereof, classified in class 544, various subclasses depending on substituents.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Date: January 13, 2006

By: 

Lauren L. Stevens
Reg. No. 36,691